Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

por Monks, N R, Blakey, D C, Curtin, N J, East, S J, Heuze, A, Newell, D R
Publicado 2001

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

por Monks, N R, Calvete, J A, Curtin, N J, Blakey, D C, East, S J, Newell, D R
Publicado 2000

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.

por Blakey, D. C., Davies, D. H., Dowell, R. I., East, S. J., Burke, P. J., Sharma, S. K., Springer, C. J., Mauger, A. B., Melton, R. G.
Publicado 1995

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma

por Fens, M H A M, Hill, K J, Issa, J, Ashton, S E, Westwood, F R, Blakey, D C, Storm, G, Ryan, A J, Schiffelers, R M
Publicado 2008

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

por Robinson, S P, McIntyre, D J O, Checkley, D, Tessier, J J, Howe, F A, Griffiths, J R, Ashton, S E, Ryan, A J, Blakey, D C, Waterton, J C
Publicado 2003